
Design Pharma: Proprietary tech enabling drug discovery and biosynthetic production.
Design Pharmaceuticals, founded with a mission to revolutionize drug discovery, focuses on leveraging proprietary ultra-high throughput bioscience technologies. The company aims to dramatically accelerate the discovery and biosynthetic production of drug candidates, particularly targeting G-protein-coupled receptors (GPCRs). By unlocking and deorphanizing these drug targets, Design Pharmaceuticals seeks to develop new treatments for diseases lacking satisfactory therapies.
Notable affiliated individuals and investors include experts in bioscience and pharmaceutical industries, though specific names are not provided. Key achievements include the development of a unique suite of technologies that significantly outpace current industry capabilities in GPCR drug discovery. The overall impact of Design Pharmaceuticals lies in its potential to transform the landscape of drug discovery, offering hope for patients with unmet medical needs.

Drug Design Methodologies
newdrugdesign.com

Seven Biosciences

ZielBio
zielbio.com

Photonic Pharma
photonicpharma.com

Generian Pharmaceuticals
generian.com

Alcinous Pharmaceuticals

PathDrugomics

1200 Pharma
1200pharma.com

BioLeap

Deep Apple Therapeutics
deepappletx.com

Redesign Science

Pepper Bio
pepper.bio

Discovery Innovations

Biosim

Septerna
septerna.com
Companies similar to Design Pharmaceuticals include Drug Design Methodologies, Seven Biosciences, ZielBio and Photonic Pharma.
Design Pharmaceuticals was founded in 2018.
Design Pharmaceuticals' headquarters is located in Cambridge, MA, US.
Design Pharmaceuticals' most recent funding round was for $5M (USD) in April 2022.
As of Apr 12, 2022, Design Pharmaceuticals has raised a total of $5M (USD).
Design Pharmaceuticals has 18 employees as of Feb 5, 2024.